{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:53:13Z","timestamp":1790268793276,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ijantimicag.2019.08.008","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T19:45:08Z","timestamp":1565120708000},"page":"547-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors"],"prefix":"10.1016","volume":"54","author":[{"given":"Li-Li","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0792-3735","authenticated-orcid":false,"given":"Shu-Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0001","unstructured":"AIDSinfo. FDA-approved HIV medicines. https:\/\/aidsinfo.nih.gov\/understanding-hiv-aids\/fact-sheets\/21\/58\/fda-approved-hiv-medicines [accessed 12 November 2018]."},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0002","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrd1660","article-title":"Integrase inhibitors to treat HIV\/AIDS","volume":"4","author":"Pommier","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0003","first-page":"11","article-title":"HIV-1 integrase strand transfer inhibitors: novel insights into their mechanism of action","volume":"2","author":"Pandey","year":"2008","journal-title":"Retrovirology (Auckl)"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0004","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JVI.01534-07","article-title":"Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137)","volume":"82","author":"Shimura","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/07853890.2014.883169","article-title":"Integrase strand transfer inhibitors in the management of HIV-positive individuals","volume":"46","author":"Mesplede","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0006","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society\u2013USA Panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0007","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1271\/bbb.68.1722","article-title":"The artificial evolution of an enzyme by random mutagenesis: the development of formaldehyde dehydrogenase","volume":"68","author":"Fujii","year":"2004","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0008","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.3390\/v7072790","article-title":"Resistance against integrase strand transfer inhibitors and relevance to HIV persistence","volume":"7","author":"Mesplede","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160087","article-title":"Therapy-emergent drug resistance to integrase strand transfer inhibitors in HIV-1 patients: a subgroup meta-analysis of clinical trials","volume":"11","author":"You","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0011","first-page":"62","article-title":"Update of the drug resistance mutations in HIV-1: Spring 2008","volume":"16","author":"Johnson","year":"2008","journal-title":"Top HIV Med"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0012","series-title":"Systematic reviews in health care: meta\u2010analysis in context","first-page":"347","article-title":"Meta-analysis in StataTM","author":"Sterne","year":"2008"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0013","article-title":"Application of generic inverse variance method in meta-analysis","author":"Xiang","year":"2012","journal-title":"J Math Med"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2019.08.008_bib0014","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S0197-2456(98)80157-8","article-title":"The performance of the DerSimonian and Laird method with non-normal random effects in meta-analysis","volume":"19","author":"Chang","year":"1998","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0015","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0016","first-page":"469","article-title":"Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate","volume":"316","author":"Seagroatt","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0017","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijantimicag.2013.02.016","article-title":"A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure","volume":"42","author":"Marcelin","year":"2013","journal-title":"Int. J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0019","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0020","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/0956462416679550","article-title":"Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: real-life analysis of the German 'WIP' cohort","volume":"28","author":"Naumann","year":"2017","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0021","doi-asserted-by":"crossref","first-page":"e39222","DOI":"10.1371\/journal.pone.0039222","article-title":"96 week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience","volume":"7","author":"Capetti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0022","unstructured":"US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf[accessed 12 November 2018]."},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0023","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0024","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0025","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","volume":"381","author":"Boyd","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0026","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2019.08.008_bib0027","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0028","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0029","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0030","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1086\/590943","article-title":"Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials","volume":"47","author":"Gupta","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0031","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/archinte.167.16.1782","article-title":"Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types","volume":"167","author":"von Wyl","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0032","doi-asserted-by":"crossref","first-page":"20057","DOI":"10.1073\/pnas.1010246107","article-title":"Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance","volume":"107","author":"Hare","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0033","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0034","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-4690-6-25","article-title":"Raltegravir, elvitegravir, and metoogravir: the birth of \u2018me-too\u2019 HIV-1 integrase inhibitors","volume":"6","author":"Serrao","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0036","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/cmdc.200900166","article-title":"Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors","volume":"4","author":"Barreca","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0037","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/AAC.00157-11","article-title":"Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase\u2013DNA complexes","volume":"55","author":"Hightower","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0038","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/QCO.0b013e32835a1de7","article-title":"Emerging patterns and implications of HIV-1 integrase inhibitor resistance","volume":"25","author":"Geretti","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0039","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.08.008_bib0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2012","journal-title":"Lancet Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919302195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919302195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:32:51Z","timestamp":1760376771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919302195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0924857919302195"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.08.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}